Dementia

The main purpose of this study is to determine the safety and efficacy of a drug called Donanemab in treating or delaying the progression of Alzheimer’s dementia. Participants will first attend a screen visit at the Royal Melbourne Hospital to ensure that they meet the criteria for the study. Once enrolled, they will be randomised in a 1:1 ratio to receive either donanemab or placebo.

The study will involve attending approximately 20 study visits at the Royal Melbourne Hospital over 76 weeks. There will also be a 48 week follow-up period. Participants will receive the drug by intravenous infusion during these visits.

Anticipated date that enrolment will close: 30 September 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

The primary purpose of this study is to help answer the following research questions:

  • How safe mirikizumab is and whether you might have any side effects when you take it?
  • How effective mirikizumab is as a treatment for Crohn’s disease when other medications may not work?
  • How mirikizumab compares to ustekinumab (a current treatment for Crohn's Disease) or placebo?

Anticipated date that enrolment will close: 31 December 2022

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Neurological Conditions (Other) - MND, Spinal Cord Injury, Stroke

The main purpose of this research is to see if the study drug helps participants’ tremors and is safe and well-tolerated in participants with essential tremor (ET). An additional purpose is to see how much of the study drug gets into the blood, and how long it takes the body to get rid of it.

Essential Tremor (ET) is a common neurological disorder, or illness related to the nervous system. It can cause shaking, also known as tremors, in the hands, arms, head, and voice. Calcium is a natural chemical in all brains that acts to change the function of some cells. One possible cause for essential tremor is that calcium is overactive in the brain. The study drug (PRAX-944) reduces the activity of calcium in the brain, which might restore the normal function of some cells and potentially help reduce the symptoms of essential tremor.

Anticipated date that enrolment will close: December 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Neurological Conditions (Other) - MND, Spinal Cord Injury, Stroke

Tourette Syndrome (TS) is a neurological (brain) disorder characterised by rapid, repetitive, and involuntary muscle movements and vocalisations (tics), often involving behavioural difficulties including attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Although TS rare, it is 2-4 times more common in males and is most prominent during childhood and adolescence.

Current treatments for TS are antipsychotic drugs which are often only moderately effective and result in a high incidence of side effects.

The investigational product, NOE-105 inhibits a specific enzyme in the body (PDE10A). The inhibition of PDE10A in the brain may lead to a reduction in the number of tics in people with TS by helping to provide a balance in the number of motor neurons (brain cells that are believed to control the tics) in the brain.

This is an open-label study which means both the researchers and study participants know which treatment is being given. All participants will receive the NOE-105 investigational product. NOE-105 will be given to participants once a day for a maximum of 12 weeks.

Anticipated date that enrolment will close: December 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Parkinsons's disease

This is a study of an experimental treatment (referred to as “study drug”) called CVL-751 as a possible treatment for Parkinson’s disease. An experimental treatment is one that has not been approved by the United States (US) Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA) in Australia or any other regulatory agency .

The main purpose of this study is to learn how well the study drug works and how safe the study drug is and to find the right dose. If you choose to participate in this study, you may receive the study drug, or you may receive placebo. A placebo is a medication with no active ingredients. It looks like the real thing but is not. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.

Anticipated date that enrolment will close: 31 December 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Parkinsons's disease

Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease. The main purpose of this study is to learn how safe the study is and how well it works. This is a randomised, double-blinded trial for people in the early stages of Parkinson's disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Fabry disease

Researchers at The Royal Melbourne Hospital are investigating several new treatments to specifically treat Fabry disease, as well as additional studies to document and monitor the manifestations of disease beyond basic medical care.

Research studies include Phase 1, 2 and 3 clinical trials as well as non-interventional and observation studies.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 2)

The purpose of this research study is to:

  • Test the safety and effectiveness of the study drug, INS068
  • Compare the study drug (INS068) to insulin degludec (Tresiba®)

Anticipated date that enrolment will close: end October 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4